Apeiron strikes again
Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by stimulating the immune system. The transaction follows in the wake of other successful in-licensing deals that Apeiron has completed in the last six months. The collaboration includes an option for Apeiron to enter into a worldwide, exclusive licensing agreement with the Cleveland Clinic relating to the compounds, and a research agreement sponsored by Apeiron relating to these compounds and approach. The approach involves tyrosine phosphatase inhibitors (TPI) inhibiting SHP-1, a protein tyrosine phosphatase that is a key negative regulator of immune cell activation. Inhibition of SHP-1 leads to activation of the immune system to combat cancer. Apeiron CEO Hans Loibner called the deal a “great collaboration for Apeiron,“ adding that he regards the compounds developed at the Cleveland Clinic as “an attractive opportunity, since they are designed to activate the patient’s own immune system.” Loibner has been a specialist for immune therapies in oncology for more than twenty years. Apeiron will also close a financing round to fund the development of its clinical pipeline.